| Marsha Sue Pharis, LPN | |
|
604 Choctaw St, Alva, OK 73717-1626 | |
| (580) 327-1112 | |
| Not Available |
| Full Name | Marsha Sue Pharis |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 604 Choctaw St, Alva, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386303006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | L0060310 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Marsha Sue Pharis, LPN 1835 Locust St, Alva, OK 73717-1769 Ph: (580) 748-1512 | Marsha Sue Pharis, LPN 604 Choctaw St, Alva, OK 73717-1626 Ph: (580) 327-1112 |
News Archive
Standard chemotherapy is a blunt force instrument against cancer - and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body.
Among patients hospitalized with community-acquired pneumonia, those who had previously received the pneumococcal vaccine had a lower risk of death and admission to the intensive care unit than patients who were not vaccinated, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.
A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.
› Verified 1 days ago
Mrs. Sandra Kay Clepper, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 604 Choctaw St, Alva, OK 73717 Phone: 580-327-1112 | |
Brisa Montes, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 604 Choctaw St, Alva, OK 73717 Phone: 580-327-1112 |